UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~April~~May 98, 2012 (~~April~~May 42, 2012)

_______________

BIOCANCELL THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware	000-53708	20-4630076
(State or other jurisdiction of incorporation)	Commission File Number	(IRS Employer Identification No.)

Beck Science Center, 8 Hartom St, Har Hotzvim, Jerusalem, Israel, 97775

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: 972-2-548-6555

(Former name or former address, if change since last report)

Check the appropriate box below if the Form 8-K filing is to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events.

~~Following~~On ~~its~~May ~~announcement~~25, ~~regarding~~2011, BioCancell Therapeutics Inc. (“the ~~successful~~Company”) ~~achievement~~was ofnotified by the ~~primary~~Food ~~endpoint~~and Drug Administration (~~drug~~“the ~~safety~~FDA”) that the primary endpoint of aits Phase ~~I/IIa~~IIb clinical trial of the drug-candidate BC-819 as a treatment for ~~advanced~~superficial ~~ovarian~~bladder cancer ~~following~~in ~~the~~patients ~~failure~~refractory ofto a standard treatment (BCG or chemotherapy) (“the Trial”), ~~and~~would ~~its~~be ~~intention~~lack toof ~~expand~~recurrence of the ~~clinical~~disease, ~~trial~~three inmonths ~~order~~after tothe ~~obtain~~commencement ~~more~~of ~~data~~treatment, onin ~~drug~~at ~~safety~~least ~~and~~nine ~~efficacy,~~of onthe ~~April~~21 4,patients ~~2012,~~participating ~~BioCancell~~in ~~Therapeutics~~the ~~Inc~~second part of the Trial. ~~announced~~Together ~~that~~with itthe ~~had~~18 ~~received~~participants in the ~~required~~first ~~regulatory~~part ~~approvals~~of tothe ~~expand~~Trial, the ~~clinical~~Trial ~~trial~~is ~~and~~expected ~~will~~to ~~commence~~include ~~patient~~39 ~~recruitment~~participants.

AsOn ~~previously~~May ~~reported~~2, ~~the~~2012, ~~safety profile of~~ the ~~drug~~Company ~~was~~published ~~found to be satisfactory, even at~~ the ~~highest~~following ~~dosage (240 mg) which was administered three times. In light of this, BioCancell intends to treat an~~ additional six patients in the expanded trial, each receiving 12 continuous weekly treatments of 240 mg of BC-819. The purpose of the expanded trial is to examine the safety of the treatment with BC-819 at a high dosage over time.information:

In- ~~addition,~~Of ~~BioCancell~~the ~~intends~~first to12 ~~examine~~participants ~~over~~treated a(out ~~longer~~of ~~period~~ the ~~phenomenon~~21 ~~observed,~~participants ~~whereby~~in ~~patients receiving~~ the ~~highest~~second ~~dosage~~part ~~showed~~of athe ~~decrease~~Trial), ~~and~~there ~~eventually~~was ~~absence,~~lack of ~~ascites~~recurrence (ain ~~fluid~~nine ~~containing~~(subject ~~cancerous~~to ~~cells that gathers in~~ the ~~abdominal~~caveat ~~cavity~~below)., ~~This~~and ~~effect continued as long as~~ the ~~patients~~Company ~~received~~has ~~treatment.~~therefore ~~Ascitic~~already ~~fluid~~met isthe aupdated ~~significant~~primary ~~side~~endpoint ~~effect~~ for ~~ovarian~~the ~~cancer patients, which adversely affects their quality of life and indicates patient deterioration~~Trial.

~~The~~- ~~expanded~~Of ~~trial~~the ~~will~~30 ~~take~~participants ~~place~~ in ~~five~~the ~~Israeli~~entire ~~medical~~Trial ~~centers:~~(first ~~Hadassah, Carmel, Meir, Wolfson~~ and ~~Sheba~~second ~~Medical~~parts) ~~Centers.~~who ~~The~~have ~~regulatory~~completed ~~committees~~three ~~approving~~months ~~clinical~~after ~~trials in each medical center have approved~~ the ~~expanded~~commencement ~~trial~~of treatment, ~~and~~19 ~~results~~(63%) ~~are~~have ~~expected~~demonstrated ~~within~~lack ~~one~~of ~~year~~recurrence.

~~This filing contains "forward~~-~~looking"~~ ~~statements,~~Of ~~including statements that may relate to~~ the ~~further~~25 ~~development~~participants ~~and~~in potential safety and efficacy of BC-819 or other products under development by BioCancell, as well as BioCancell's development strategy. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the ~~results~~entire ofTrial ~~BioCancell~~who to differ materially from those indicated by these forward-looking statements, including, among others, the risk that the U.S. Food and Drug Administration may require changes to the protocols and informed consents for clinical trials, which changes may have acompleted ~~material~~12 ~~adverse~~months ~~effect~~after on the ~~timing~~commencement of, ~~and BioCancell's ability to conduct~~treatment, ~~those~~14 ~~clinical~~(56%) ~~trials,~~have ~~risks~~demonstrated ~~related~~lack ~~to the clinical advancement~~ of BioCancell's products, including, but not limited, to the risk that clinical trials may not demonstrate safety and efficacy sufficient to obtain the requisite regulatory approvals or to result in a marketable product and risks related to the potential for others to develop similar productsrecurrence. ~~BioCancell does not undertake any obligation to update forward-looking statements.~~

In addition, in the Company’s Phase IIb clinical trial of BC-819 as a treatment for pancreatic cancer, eight patients have commenced treatment, and the results regarding the first 12 patients are expected later this year.

The aforementioned clinical trials are open-label. Information about expectations regarding the Company meeting clinical trial criteria and the date of completion of clinical trials, are forward-looking statements. Forward-looking statements are statements regarding uncertain future facts, based on information and estimates currently held. Some such expectations may not be realized, or may be realized in part, for the following reasons, inter alia: (a) The aforementioned results are a preliminary indication that may change after further testing, validation, and additional data-gathering; (b) In addition to the primary endpoint, the Company will carry out all statistical analyses originally planned for the Trial; (c) Patient recruitment in the aforementioned trials is not yet complete; (d) The Company may need to raise additional funds in order to complete its clinical trials.

After the Trial is completed, the Company intends to disclose final results and the aforementioned data are subject to change. As discussed with the FDA, after the completion of the Trial, the aforementioned updated criterion will be analyzed for all 39 participants in the Trial.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BIOCANCELL THERAPEUTICS, INC.
Dated: April 9, 2012	By:	/s/ Avraham Hampel
Dated: May 8, 2012	By:	/s/ Avraham Hampel
		Avraham Hampel
		Company Secretary

Filing Compare · BIOCANCELL THERAPEUTICS INC.